Global ‘PsoriasIS NOT CONTAGIOUS’ campaign for World Psoriasis Day 2020Fishawack Health launches global disease awareness campaign, supported by the community of Psoriasis Warriors to de-stigmatize psoriasis during Share XGlobal ‘PsoriasIS NOT CONTAGIOUS’ campaign for World Psoriasis Day 2020https://pharmaphorum.com/partner-content/global-psoriasis-not-contagious-campaign-for-world-psoriasis-day-2020/
Popit and Almirall’s new app tracks adherence to psoriasis medFinnish startup Popit has joined with Spain’s Almirall to produce an app that tracks whether patients have taken Share XPopit and Almirall’s new app tracks adherence to psoriasis medhttps://pharmaphorum.com/news/popit-and-almiralls-new-app-tracks-adherence-to-psoriasis-med/
BMS’ deucravacitinib psoriasis pill outperforms Amgen’s Otezla in phase 3Bristol-Myers Squibb could be on the verge of a major coup in psoriasis after its deucravacitinib pill outperformed Share XBMS’ deucravacitinib psoriasis pill outperforms Amgen’s Otezla in phase 3https://pharmaphorum.com/news/bms-deucravacitinib-psoriasis-pill-outperforms-amgens-otezla-in-phase-3/
Holistic immunology: Supporting patients at every stage of their journeyAs part of our series from leaders at Janssen, the company’s Max Pahlow looks at how approaches to Share XHolistic immunology: Supporting patients at every stage of their journeyhttps://pharmaphorum.com/r-d/views-analysis-r-d/holistic-immunology-supporting-patients-at-every-stage-of-their-journey/
Phase 3 wins put Dermavant closer to filing Otezla rival tapinarofJust two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could Share XPhase 3 wins put Dermavant closer to filing Otezla rival tapinarofhttps://pharmaphorum.com/news/phase-3-wins-put-dermavant-closer-to-filing-otezla-rival-tapinarof/
UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trialBelgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, Share XUCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trialhttps://pharmaphorum.com/news/ucbs-il-17-latecomer-bimekizumab-beats-cosentyx-in-psoriasis-trial/
Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in psoriasisEli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate, Share XLilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in psoriasishttps://pharmaphorum.com/news/lillys-mirikizumab-tops-novartis-blockbuster-cosentyx-in-psoriasis/
Towards Patient Centricity: LEO PharmaIndustry plays a pivotal role in making sure patient needs are not overlooked by the wider healthcare community. Share XTowards Patient Centricity: LEO Pharmahttps://pharmaphorum.com/views-analysis-patients/towards-patient-centricity-leo-pharma/
UCB’s bimekizumab tops J&J’s Stelara in psoriasis studyThe first phase 3 data with UCB’s key pipeline drug bimekizumab show that it hit all its efficacy Share XUCB’s bimekizumab tops J&J’s Stelara in psoriasis studyhttps://pharmaphorum.com/news/ucbs-bimekizumab-tops-jjs-stelara-in-psoriasis-study/
